CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is also involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. The company was founded in 2010 and is headquartered in Seoul, South Korea.
तुलना करने के लिए मीट्रिक्स | 308430 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध308430पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −45.5x | −6.3x | −0.5x | |
PEG अनुपात | - | 0.05 | 0.00 | |
क़ीमत/बुक | 13.9x | 1.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 161.5x | 2.5x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 104.1% | 51.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.5% | 7.3% | अनलॉक करें |